News|Articles|December 15, 2016

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-01-04-2017
  • Volume 12
  • Issue 1

DuPont Receives Grant from Bill & Melinda Gates Foundation

DuPont received a grant from the Bill & Melinda Gates Foundation to produce pharmaceutical proteins.

On Dec. 15, 2016, DuPont Industrial Biosciences announced the receipt of a grant from the Bill & Melinda Gates Foundation to support a research project aimed at creating new production systems to enable affordable, protein-based biologic medications. Through a grant from the Bill & Melinda Gates Foundation, DuPont will apply its capabilities in the areas of protein engineering, pathway engineering, and cell factories to the field of protein drugs. When applied to pharmaceutical protein production, this approach has the potential to enable rapid scale-up and lower costs at high volumes, making protein drugs such as monoclonal antibodies potentially suitable for infectious diseases, effectively managing outbreaks and providing affordable supply to people around the world.

The Bill & Melinda Gates Foundation has invested in drug discovery research through a variety of mechanisms. In a time when public-funded research is diminishing, companies such as DuPont are engaging in new ways with stakeholders across the public and private sectors to tackle large societal challenges, Dupont said in a press release.

Source: DuPont Industrial Biosciences


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.